Phase 1/2 Study of PX-866 and Cetuximab (Oncothyreon, Inc. PX-866-003)

Trial Profile

Phase 1/2 Study of PX-866 and Cetuximab (Oncothyreon, Inc. PX-866-003)

Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Sonolisib (Primary) ; Cetuximab
  • Indications Colorectal cancer; Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Oncothyreon
  • Most Recent Events

    • 18 May 2015 Status changed from active, no longer recruiting to completed as reported by
    • 21 May 2013 85 and 83 patients have been enrolled in the colorectal cancer and head and neck cancer groups, with primary efficacy data expected later this month and by year end respectively, according to the Q1 2013 financial report for Oncothyreon.
    • 13 May 2013 Planned End Date changed from 1 Apr 2013 to 1 Jan 2014 as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top